Management of Generalized Myasthenia Gravis in Pediatric Patients
November 8th 2024Panelists discuss how generalized myasthenia gravis (gMG) presents unique diagnostic challenges in pediatric populations, review current standard-of-care management strategies for children and adolescents, and highlight promising investigational treatments for pediatric gMG.
Use of Targeted Agents in Generalized Myasthenia Gravis
November 8th 2024Panelists discuss how they select patients for FcRn and complement inhibitor therapies, integrate these treatments into long-term management plans, monitor patients on these therapies, and approach treatment for those with inadequate disease control on traditional or targeted therapies for generalized myasthenia gravis.
Dosing Regimens and Treatment Efficacy of FcRn Inhibitors in Generalized Myasthenia Gravis
November 6th 2024Panelists discuss how they approach and potentially adapt the dosing and administration regimens of approved and investigational FcRn inhibitors in their myasthenia gravis patients, considering the prescribed guidelines and individual patient needs.
Nipocalimab and FcRn Inhibitors in Generalized Myasthenia Gravis
November 6th 2024Panelists discuss how recent phase 3 trial results for nipocalimab and batoclimab, both neonatal Fc receptor (FcRn) inhibitors, demonstrate efficacy and safety in different generalized myasthenia gravis patient populations, comparing these findings with earlier phase 2 data and evaluating their potential impact on treatment approaches.
Combination Therapy in Generalized Myasthenia Gravis and Treatment of Newly Diagnosed Patients
November 6th 2024Panelists discuss how they approach combination therapy in generalized myasthenia gravis (gMG), including patient selection and timing, while also examining how the availability of newer targeted treatments has influenced their approach to managing newly diagnosed patients.
Pathophysiology and Standard of Care in Generalized Myasthenia Gravis
November 4th 2024Panelists discuss how the current understanding of myasthenia gravis pathophysiology is informing the development of targeted treatments, alongside reviewing the standard of care for generalized myasthenia gravis (gMG).